Sabril (vigabatrin) - Important Safety Information from sanofi-aventis as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 05/07/2010

 

Problem Or Issue:
Important safety information communication from sanofi-aventis on abnormal brain MRI findings and movement disorders in patients treated with Sabril®(Vigabatrin).

Important Safety Information - Sabril (vigabatrin)


« Back